Bitherapy, or combined therapies, is designed to treat patients infected with the hepatitis C virus.
The two compounds used are:
- pegylated interferon alpha (peginterferon)
- and ribavirin.
The treatment lasts for from 6 months to 1 year depending on the virus genotype and on its level in the body.
The recovery rate after treatment is 55%, all genotypes combined. Approximately 10% of patients respond positively to treatment but relapse within 6 months. The remaining patients, approximately 35%, do not respond at all to treatment.
The hepatitis C virus can be targeted by bitherapy. © DR Credits